A21P (p.Ala21Pro) variant of EGFR (Epidermal growth factor receptor)
A21P (p.Ala21Pro) in EGFR (Epidermal growth factor receptor) is a missense change. Clinical records from EBI and UniProt describe it as benign. The record also includes variant effect predictions, experimental measurements, and structural context.
A21P (p.Ala21Pro) variant details
- p.Ala21Pro
- 1000Genomes rs373129709
- ESP rs373129709
- ExAC rs373129709
- TOPMed rs373129709
- Benign
- Missense
- MetaLR 0.37
- MetaSVM -0.70
- SIFT 0.21
- EBI: Benign
- UniProt: Benign
- Structural context available
- Dabrafenib and Cetuximab HT-29 cells, base editing z-scores (predicted consequen: score -0.636